Health TrialsbyHealthPanel

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

ConditionsObesityOverweightDiabetes Mellitus, Type 2
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorEli Lilly and Company

About this trial

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Have type 2 diabetes

Have an HbA1c ≥7.5% to ≤10.5% at screening

Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening

Diet and exercise

Disqualifiers

Have any form of diabetes other than type 2 diabetes

Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening

acute myocardial infarction

cerebrovascular accident (stroke)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Macupatide

    Drug

    Administered SC

  • Eloralintide

    Drug

    Administered SC

  • Macupatide Placebo

    Drug

    Administered SC

  • Eloralintide Placebo

    Drug

    Administered SC

Treatment groups

200 Participants
are divided into 4 treatment groups
Group A: Macupatide (Macupatide + Eloralintide Placebo)Experimental treatment 2 interventions
Group B: Eloralintide (Elorlintide + Macupatide Placebo)Experimental treatment 2 interventions
Group C: Macupatide + EloralintideExperimental treatment 2 interventions
Group D: Placebo (Macupatide Placebo + Elorlintide Placebo)Placebo comparator 2 interventions

Trial outcomes

Primary outcomes

1

Percent Change from Baseline in Body Weight

Time frame
Baseline, Week 32

Secondary outcomes

1

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame
Baseline, Week 32
2

Change from Baseline in Body Mass Index (BMI)

Time frame
Baseline, Week 32
3

Change from Baseline in Fasting Glucose

Time frame
Baseline, Week 32

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov
Apply now